Market Trends of Injectable Anti-diabetic Drugs Industry
Dulaglutide Segment Occupied the Highest Market Share in the Injectable Anti-diabetic Drugs Market in the current year
The Dulaglutide segment held the highest share in the injectable anti-diabetic drugs market in the current year.
According to the International Diabetes Federation's (IDF) latest estimates, the adult diabetes population is approximately 537 million, and this number is going to increase by 643 million in 2030. Technological advancements have increased over the period, leading to several modifications either in the GLP-1RA drug or the formulations being developed.
GLP1RAs have been available internationally and are recommended for use when escalation of treatment for type 2 diabetes is required after metformin and lifestyle management. They can be safely used with all other glucose-lowering therapies except vildagliptin. Dulaglutide (Trulicity) is a weekly subcutaneous GLP1RA that is highly effective for reducing HbA1c with additional weight loss and cardiorenal protection benefits. Therapy with dulaglutide allows many patients to reach and maintain target HbA1c without insulin and/or sulfonylureas, eliminating the associated hypoglycemia risk. GLP1RAs elicit greater weight reduction and are recommended over SLGT2 inhibitors when cerebrovascular disease other than heart failure or renal disease predominates.
Dulaglutide is fully funded for patients meeting special authority criteria in some countries. For instance, New Zealand guidelines recommend offering GLP1RAs to all patients with HbA1c levels above target, especially when GLP1RA use would provide additional reductions in cardiovascular risk and/or permit reduction or cessation of other therapies that contribute to weight gain or hypoglycemia.
Owing to the rising rate of obesity, growing genetic factors for type-2 diabetes, and the increasing prevalence and government support initiatives, it is likely that the market will continue to grow.
North American region held the highest market share in the Injectable Anti-diabetic Drugs Market in the current year
North America held the highest market share in the Injectable Anti-diabetic Drugs Market in the current year.
The Centers for Disease Control and Prevention (CDC) National Diabetes Statistics Report 2022 estimated that more than 130 million adults are living with diabetes or prediabetes in the United States. Type 2 diabetes is more common, and diabetes is more consequential among communities of color, those who live in rural areas, and those with less education, lower incomes, and lower health literacy.
Health Canada is the third regulatory agency to provide more options for people interested in GLP-1 agonists. It approved the first and only GLP-1 agonist pill (Rybelsus by Novo Nordisk) for people with type 2 diabetes recently after approval by the European Medicines Agency and approval in the U.S. GLP-1 RAs can be taken alone or in combination with other treatments for type 2 diabetes to improve blood glucose management, i.e., time in range, in addition to lowering blood glucose, they benefit heart health by reducing the risk of heart attack, stroke, and heart-related death. This is important because people with type 2 diabetes are at substantially higher risk of heart disease than those without diabetes.
Furthermore, the market players are adopting various strategies such as collaborations, partnerships, mergers, acquisitions, and expansions for new products to increase market share. For instance, Eli Lilly and Boehringer Ingelheim together have an alliance in developing and commercializing Basaglar (Insulin Glargine). However, the companies are working on various innovations such as Biocon is developing Insulin Tregopil, an oral prandial insulin tablet, for the treatment of type-1 and type-2 diabetes mellitus. The fast-acting oral insulin could improve post-prandial glucose control with reduced side effects and greater adherence, thus holding the promise to transform type-1 management. Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, is working to bring the first oral insulin.
The variables mentioned above, together with the increased incidence of diabetes caused by inactivity, are anticipated to propel the market forward during the projected time.
